promotional_banner

Free Webinar: The End Game – Payer Engagement

pharmafile | November 21, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Webinar, biotech, drugs, pharma, pharmaceutical 

In our latest free to attend webinar, we have joined up with NDA to bring you the latest market access strategies and will also cover the importance of early planning in product development.

Laurie Smaldone Alsup, MD, COO/CSO of NDA, will speak on these key topics:

  • Insight into the how to avoid market delays that impact patients and ultimately reimbursement
  • The importance of early planning, pressure testing and preparation for the make or break end game
  • How to convince payers that your product brings important value to patients and to the system.

Beyond these key areas, she will share proven methods to critique and provide strategy through expert panels that pressure test the pivotal trial designs and value documentation – with these methods helping align companies internally and more efficiently focus investments.

It will also be detailed how cross functional teams can benefit from these strategies, including regulatory, clinical, outcomes research, marketing, market access, commercial and medical affairs operations.

The webinar will begin at 3pm GMT, 4pm CET, 10am EST, 11am EDT, on Thursday the 30th of November.

Click here to book your place today. If you require further information, please do not hesitate to contact us.

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content